Brief: Cyclo Therapeutics Announces Completion Of Enrollment In Its Extension Protocol To The Phase I Trial To Evaluate Trappsol Cyclo
26/02/2020 13:08
Feb 26 (Reuters) - Ctd Holdings Inc CTDH.PK :
* CYCLO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
ITS
EXTENSION PROTOCOL TO THE PHASE I TRIAL TO EVALUATE TRAPPSOL®
CYCLO™ FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C
Source text for Eikon: ID:nBw4yr9kBa
Further company coverage: CTDH.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug